Protagonist Therapeutics Files 8-K
Ticker: PTGX · Form: 8-K · Filed: Nov 7, 2024 · CIK: 1377121
Sentiment: neutral
Topics: 8-K, financial-reporting
TL;DR
Protagonist Therapeutics filed an 8-K on Nov 7, 2024, for financial updates.
AI Summary
Protagonist Therapeutics, Inc. filed an 8-K on November 7, 2024, reporting on its results of operations and financial condition, as well as financial statements and exhibits. The filing does not contain specific financial figures or operational updates beyond the general reporting categories.
Why It Matters
This 8-K filing indicates Protagonist Therapeutics is providing updates on its financial condition and operations, which could be relevant for investors monitoring the company's status.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for reporting financial information and does not appear to contain any immediately alarming or significant negative news.
Key Players & Entities
- Protagonist Therapeutics, Inc. (company) — Registrant
- November 7, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-37852 (company_id) — Commission File Number
- 98-0505495 (tax_id) — IRS Employer Identification No.
FAQ
What specific financial information is being reported in this 8-K?
The filing indicates it pertains to 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits', but specific figures are not detailed in the provided text.
When was this 8-K filed?
The 8-K was filed on November 7, 2024.
What is the company's state of incorporation?
Protagonist Therapeutics, Inc. is incorporated in Delaware.
What is the Commission File Number for Protagonist Therapeutics, Inc.?
The Commission File Number is 001-37852.
What is the IRS Employer Identification Number for the company?
The IRS Employer Identification Number is 98-0505495.
Filing Stats: 549 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2024-11-07 16:09:23
Key Financial Figures
- $0.00001 — h registered Common Stock, par value $0.00001 PTGX The Nasdaq Stock Market LLC
Filing Documents
- tm2427679d1_8k.htm (8-K) — 26KB
- tm2427679d1_ex99-1.htm (EX-99.1) — 79KB
- tm2427679d1_ex99-1img001.jpg (GRAPHIC) — 5KB
- 0001104659-24-115303.txt ( ) — 292KB
- ptgx-20241107.xsd (EX-101.SCH) — 3KB
- ptgx-20241107_lab.xml (EX-101.LAB) — 33KB
- ptgx-20241107_pre.xml (EX-101.PRE) — 22KB
- tm2427679d1_8k_htm.xml (XML) — 4KB
02. Results of Operations
Item 2.02. Results of Operations and Financial Condition. On November 7, 2024, Protagonist Therapeutics, Inc. reported its financial results for the third quarter ended September 30, 2024. A copy of the press release titled "Protagonist Reports Third Quarter 2024 Financial Results and Provides Corporate Update" is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto and is incorporated herein by reference.
01 Financial Statements
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release, dated November 7, 2024, titled "Protagonist Reports Third Quarter 2024 Financial Results and Provides Corporate Update." 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). The information in this report, including the exhibit hereto, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Protagonist Therapeutics, Inc., whether made before or after the date hereof, regardless of any general incorporation language in such filing. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Protagonist Therapeutics, Inc. Dated: November 7, 2024 By: Asif Ali Asif Ali Chief Financial Officer